Company Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.
It offers test services through physicians and their patients.
The company was founded in 2007 and is headquartered in Friendswood, Texas.
| Country | United States |
| IPO Date | Jul 25, 2019 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 710 |
| CEO | Derek J. Maetzold |
Contact Details
Address: 505 South Friendswood Drive Friendswood, Texas United States | |
| Website | https://castlebiosciences.com |
Stock Details
| Ticker Symbol | CSTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001447362 |
| CUSIP Number | 14843C105 |
| ISIN Number | US14843C1053 |
| Employer ID | 77-0701774 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President & Director |
| Frank Stokes | Chief Financial Officer & Treasurer |
| Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Bernhard E. Spiess | Company Secretary |
| Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
| Keli Greenberg | Vice President of Human Resources & Executive Director of Human Resources |
| Kevin Doman | Vice President of Sales |
| Tobin W. Juvenal | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 4 | Filing |
| Dec 11, 2024 | 4 | Filing |
| Dec 11, 2024 | 4 | Filing |
| Dec 11, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |